Clinical Trial Detail

NCT ID NCT03481816
Title Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines
Recruitment Active, not recruiting
Gender male
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

prostate cancer

Therapies

ETBX-051 + ETBX-061 + ETBX-071

Age Groups: senior adult

No variant requirements are available.